Lithia Motors, Inc. logo LAD - Lithia Motors, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 19
HOLD 6
SELL 1
STRONG
SELL
0
| PRICE TARGET: $345.00 DETAILS
HIGH: $380.00
LOW: $300.00
MEDIAN: $355.00
CONSENSUS: $345.00
UPSIDE: 24.74%

Stock News

Lithia & Driveway (LAD) Reports First Quarter Results

Lithia & Driveway (LAD) Reports First Quarter Results

Key Highlights Record first quarter revenues of $9.3 billion Used vehicle revenue increased 4.6% on a same store basis in the quarter Used retail GPUs increased 9%, or $133, sequentially Aftersales revenue increased 3.8%, gross profit increased by 5.7% and gross margin was 58.7%, a 100-basis point increase, on a same-store basis Driveway Finance Corporation achieved record originations of $840 million, with an 18.0% penetration rate and an average FICO score of 750 in the quarter First quarter diluted earnings per share of $4.28 and adjusted diluted earnings per share of $7.34 Repurchased $259 million of shares, representing 4.0% of outstanding shares in the quarter MEDFORD, Ore., April 29, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD), the largest global automotive retailer, today reported financial results for the first quarter of 2026.

Apr 29, 2026 01:30 AM globenewswire.com
Top 25 High-Growth Dividend Stocks For April 2026

Top 25 High-Growth Dividend Stocks For April 2026

The April 2026 Top 25 High Growth Dividend Stocks list targets quality companies trading below intrinsic value, averaging a 1.52% yield and 17.7% five-year dividend growth. Screened stocks appear ~34% undervalued by dividend yield theory, with an estimated +21% annualized long-term return potential. MSCI, WING, ZTS, INTU, and MSFT stand out for attractive valuations, robust dividend growth, and strong projected EPS growth.

Apr 07, 2026 05:33 AM seekingalpha.com
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion defici.

Mar 27, 2026 03:00 AM businesswire.com
Lithia Motors, Inc. (NYSE:LAD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lithia Motors, Inc. (NYSE:LAD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Lithia Motors, Inc. (NYSE: LAD - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price

Mar 26, 2026 10:37 PM defenseworld.net
Lithia & Driveway Donates Over $500,000 to Automotive Programs Nationwide to Support the Next Generation of Automotive Technicians

Lithia & Driveway Donates Over $500,000 to Automotive Programs Nationwide to Support the Next Generation of Automotive Technicians

MEDFORD, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced a donation of over $500,000 to automotive programs nationwide as part of their Helping Drive the Future Initiative. Through the donation, 11 colleges and universities will each receive $50,000 to help students achieve success in their programs, with funds supporting new equipment, technology, and other curriculum needs.

Mar 10, 2026 01:30 AM globenewswire.com

Price Targets